Clinical Trial

Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)

Name: Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003) — clinical trial record (NCT06561399)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

This is an Open-label, Multicenter, Phase II clinical trial to evaluate the efficacy and safety of Transcatheter arterial chemoembolization (TACE), Lenvatinib combination with Sintilimab (Triple Therapy) sequential radiotherapy in patients with Unresectable Hepatocellular Carcinoma (uHCC).

Trial Details

NCT Number	NCT06561399
Lead Sponsor	Fujian Provincial Hospital
Conditions	Hepatocellular Carcinoma Non-resectable
Enrollment	28 participants
Start Date	2024-08-15
Primary Completion	2027-07-01 (estimated)
Study Completion	2028-07-01 (estimated)
Updated on ClinicalTrials.gov	2024-08-20